Future Science Group (FSG) today announced the publication of a new article in Future Science OA examining the effects of diabetes on hospitalization risk, chances of multiple admissions, and length of hospitalization stay, for patients suffering from solid-organ malignancies such as breast, colorectal, lung and pancreas, among others.
Presence of diabetes mellitis is understood to be associated with an increased risk of onset of, and mortality owing to, solid-organ malignancy. In addition, hyperglycemia has been linked with mortality. What's more, both diabetes and cancer place a high economic burden on healthcare systems. However, data concerning interactions between diabetes, solid-organ malignancy and hospitalization are lacking.
The study saw the group, from Mayo Clinic (AZ, USA), utilize their institutional cancer registry to identify 4620 patients with solid-organ malignancy meeting their criteria, of which 732 had a coexisting diabetes diagnosis. Hospitalizations and multiple hospitalizations were significantly more frequent among patients with diabetes, and hospital stay was also half a day longer on average.
"This is the first analysis to determine that DM coexisting with solid-organ malignancies is associated with risk of hospitalization and multiple hospitalizations," commented Nina Karlin, corresponding author. "Such findings are thought-provoking and have significant economic implications. Further study is needed so that mitigating strategies can be developed."
"With the dramatic economic and health impacts of both diabetes and solid-organ malignancy, the lack of literature examining these factors together is surprising," commented Francesca Lake, Managing Editor. "There is clearly a need for further understanding of the interplay between these diseases, both to improve patient outcomes and reduce the burden on healthcare resources."
The article is available free to read at: http://www.
About Future Science OA
Launched in March 2015, Future Science OA is the inaugural gold open access journal from Future Science Group. It publishes articles covering research of application to human health, and utilizes a CC-BY license. Future Science OA embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. Negative and early-phase research will be considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.